journal article·2024-05

Near-infrared fluorescent probes for imaging of amyloid-β at different stages in monitoring Alzheimer's disease

Xueqi Zhao, Ruiwen Zhang, Dexiang Hu, Mengzhen Li, Yaoyang Liu, Xiaomeng Xiu, Hongwei Jia, Hanxun Wang, Zhenli Li, Yang Liu, Huali Yang, Maosheng Cheng

Dyes and Pigments· Volume 224
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Alzheimer's disease research and treatments · Cholinesterase and Neurodegenerative Diseases · Tryptophan and brain disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (96)

Show source-provided references
1. World Alzheimer report 2018 (https://www.alzint.org/u/WorldAlzheimerReport2018.pdf).
2. Kung · ACS Med Chem Lett · 2012 · 3 · 26510.1021/ml300058m ↗
3. The β-amyloid hypothesis in Alzheimer's disease: seeing is believing10.1021/ml300058m ↗
4. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory10.1038/nm1782 ↗
5. Bringing amyloid into focus10.1038/nbt0505-552 ↗
6. PET molecular imaging for pathophysiological visualization in Alzheimer's disease10.1007/s00259-022-05999-z ↗
7. Advances in development of fluorescent probes for detecting amyloid-β aggregates10.1038/aps.2015.155 ↗
8. Protein aggregate characterization in models of neurodegenerative disease10.1007/978-1-59745-562-6_6 ↗
9. Near-infrared fluorescent probes as imaging and theranostic modalities for amyloid-beta and tau aggregates in Alzheimer's disease10.1021/acs.jmedchem.1c01619 ↗
10. APP/Aβ structural diversity and Alzheimer's disease pathogenesis10.1016/j.neuint.2017.08.007 ↗
11. Mechanisms for the insertion of toxic, fibril-like β-amyloid oligomers into the membrane10.1021/ct300916f ↗
12. Intracellular amyloid-β in Alzheimer's disease10.1038/nrn2168 ↗
13. Distinct dimerization for various alloform-ms of the amyloid-beta protein: abeta(1-40), Abeta(1-42), and Abeta(1-40) (D23N)10.1021/jp2126366 ↗
14. The nature of the amyloid-β monomer and the monomer-oligomer equilibrium10.1016/j.bpj.2010.12.1318 ↗
15. Sequence‐based modeling of Aβ42 soluble oligomers10.1002/bip.20675 ↗
16. High-resolution atomic force microscopy of soluble Aβ42 oligomers10.1016/j.jmb.2006.01.042 ↗
17. Peptide fibrillization10.1002/anie.200700861 ↗
18. Water-soluble Aβ (N-40, N-42) oligomers in normal and alzheimer disease brains (∗)10.1074/jbc.271.8.4077 ↗
19. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease10.1016/S0002-9440(10)65184-X ↗
20. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis10.1126/science.1079469 ↗
21. A century-old debate on protein aggregation and neurodegeneration enters the clinic10.1038/nature05290 ↗
22. Soluble Aβ oligomer production and toxicity10.1111/j.1471-4159.2011.07478.x ↗
23. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons10.1523/JNEUROSCI.19-20-08876.1999 ↗
24. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide10.1038/nrm2101 ↗
25. Intracellular amyloid-β in Alzheimer's disease10.1038/nrn2168 ↗
26. Reciprocal disruption of neuronal signaling and Aβ production mediated by extrasynaptic NMDA receptors: a downward spiral10.1007/s00441-013-1789-1 ↗
27. Amino acids variations in Amyloid-β peptides, mitochondrial dysfunction, and new therapies for Alzheimer's disease10.1007/s10863-009-9246-2 ↗
28. Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss10.1073/pnas.1834302100 ↗
29. A specific amyloid-β protein assembly in the brain impairs memory10.1038/nature04533 ↗
30. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory10.1038/nm1782 ↗
31. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease10.1093/hmg/dds360 ↗
32. Aβ monomer induces phosphorylation of Tau at Ser‐214 through β2AR‐PKA‐JNK signaling pathway10.1096/fj.201902230RR ↗
33. Kinetic analysis of aggregated amyloid-β peptide clearance in adult bone-marrow-derived macrophages from APP and CCL2 transgenic mice10.1007/s11481-006-9049-8 ↗
34. Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer's disease10.1038/nature06616 ↗
35. In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers10.1002/ange.200500845 ↗
36. Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-β deposits10.1021/ja9047043 ↗
37. Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid beta species in Alzheimer's disease10.1021/ja405239v ↗
38. Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease10.1073/pnas.1505420112 ↗
39. Tuning the stereo-hindrance of a curcumin scaffold for the selective imaging of the soluble forms of amyloid beta species10.1039/C7SC02050C ↗
40. Engineering of donor-acceptor-donor curcumin analogues as near-infrared fluorescent probes for in vivo imaging of amyloid-β species10.7150/thno.68679 ↗
41. Chemical fluorescent probe for detection of Aβ oligomers10.1021/jacs.5b06190 ↗
42. A spiropyran-based fluorescent probe for the specific detection of β-amyloid peptide oligomers in Alzheimer's disease10.1039/C6CC02741E ↗
43. Fluoro-substituted cyanine for reliable in vivo labelling of amyloid-β oligomers and neuroprotection against amyloid-β induced toxicity10.1039/C7SC03974C ↗
44. Amyloid-β oligomer targeted theranostic probes for in vivo NIR imaging and inhibition of self-aggregation and amyloid-β induced ROS generation10.1016/j.talanta.2020.121830 ↗
45. Fluorescent imaging of β-amyloid using BODIPY based near-infrared off–on fluorescent probe10.1021/acs.bioconjchem.8b00623 ↗
46. Highly specific detection of Aβ oligomers in early Alzheimer's disease by a near-infrared fluorescent probe with a “V-shaped” spatial conformation10.1039/C9CC08894F ↗
47. Curcumin complex analogues as near-infrared fluorescent probes for monitoring all Aβ species in the early Alzheimer's disease model10.1021/acschemneuro.1c00419 ↗
48. A near‐infrared probe for detecting and interposing amyloid beta oligomerization in early Alzheimer's disease
49. The structure of nanotubes formed by diphenylalanine, the core recognition motif of Alzheimer's β-amyloid polypeptide10.1039/B603080G ↗
50. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy10.1002/ana.1009 ↗
51. Magnetite/ceria nanoparticle assemblies for extracorporeal cleansing of amyloid‐β in Alzheimer's disease10.1002/adma.201807965 ↗
52. In vivo near-infrared fluorescence imaging selective for soluble amyloid β aggregates using y-shaped BODIPY derivative10.1021/acs.jmedchem.3c01057 ↗
53. Detection of Aβ oligomers in early Alzheimer's disease diagnose by in vivo NIR-II fluorescence imaging10.1016/j.snb.2022.131481 ↗
54. In vivo detection of amyloid-β deposits by near-infrared imaging using an oxazine-derivative probe10.1038/nbt1085 ↗
55. In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers10.1002/ange.200500845 ↗
56. Inhibition of beta‐amyloid peptide aggregation by multifunctional carbazole‐based fluorophores10.1002/ange.201104150 ↗
57. A theranostic agent for in vivo near-infrared imaging of β-amyloid species and inhibition of β-amyloid aggregation10.1016/j.biomaterials.2016.03.047 ↗
58. Multifunctional theranostic carbazole-based cyanine for real-time imaging of amyloid-β and therapeutic treatment of multiple pathologies in Alzheimer's disease10.1039/D3TB00082F ↗
59. Diarylethene based fluorescent switchable probes for the detection of amyloid-β pathology in Alzheimer's disease10.1039/C4CC07656G ↗
60. Aminonaphthalene 2-cyanoacrylate (ANCA) probes fluorescently discriminate between amyloid-β and prion plaques in brain10.1021/ja3063698 ↗
61. In vivo fluorescence imaging of β-amyloid plaques with push–pull dimethylaminothiophene derivatives10.1039/C5CC06628J ↗
62. BODIPY-based molecular probe for imaging of cerebral β-amyloid plaques10.1021/cn3000058 ↗
63. Smart near-infrared fluorescence probes with donor–acceptor structure for in vivo detection of β-amyloid deposits10.1021/ja4052922 ↗
64. Dicyanovinylnaphthalenes for neuroimaging of amyloids and relationships of electronic structures and geometries to binding affinities10.1073/pnas.1214134109 ↗
65. Highly sensitive near-infrared fluorophores for in vivo detection of amyloid-β plaques in Alzheimer's disease10.1021/acs.jmedchem.5b00861 ↗
66. Amyloid-β deposits target efficient near-infrared fluorescent probes: synthesis, in vitro evaluation, and in vivo imaging10.1021/acs.analchem.5b04441 ↗
67. Smart D-π-A type near-infrared Aβ probes: effects of a marked π bridge on optical and biological properties10.1021/acs.analchem.7b02246 ↗
68. Novel D-A-D based near-infrared probes for the detection of β-amyloid and Tau fibrils in Alzheimer's disease10.1039/C8CC05259J ↗
69. N, O-Benzamide difluoroboron complexes as near-infrared probes for the detection of β-amyloid and tau fibrils10.1039/D0CC02820G ↗
70. BODIPY dyes and their derivatives: syntheses and spectroscopic properties10.1021/cr078381n ↗
71. Evaluation of N, O-Benzamide difluoroboron derivatives as near-infrared fluorescent probes to detect β-amyloid and tau tangles10.1016/j.ejmech.2021.113968 ↗
72. Rational design of molecular rotor-based fluorescent probes with bi-aromatic rings for efficient in vivo detection of amyloid-β plaques in Alzheimer's disease10.1016/j.ejmech.2022.114715 ↗
73. Near-infrared fluorescent probes with rotatable polyacetylene chains for the detection of amyloid-β plaques10.1021/acs.jpcb.0c08845 ↗
74. A high affinity red fluorescence and colorimetric probe for amyloid β aggregates10.1038/srep23668 ↗
75. Coumarin-based small-molecule fluorescent chemosensors10.1021/acs.chemrev.9b00145 ↗
76. A coumarin-based fluorescent probe for selective and sensitive detection of thiophenols and its application10.1021/ac403885n ↗
77. Development of phenothiazine-based theranostic compounds that act both as inhibitors of β-amyloid aggregation and as imaging probes for amyloid plaques in Alzheimer's disease10.1021/acschemneuro.6b00380 ↗
78. Aβ plaque-selective NIR fluorescence probe to differentiate Alzheimer's disease from tauopathies10.1016/j.bios.2017.06.030 ↗
79. A hemicyanine derivative for near-infrared imaging of β-amyloid plaques in Alzheimer's disease10.1016/j.ejmech.2019.07.005 ↗
80. Synthesis and evaluation of curcumin-based near-infrared fluorescent probes for the in vivo optical imaging of amyloid-β plaques10.1016/j.bioorg.2021.105167 ↗
81. Rational design of quinoxalinone-based red-emitting probes for high-affinity and long-term visualizing amyloid-β in vivo10.1021/acs.analchem.2c01046 ↗
82. Design and development of benzothiazole-based fluorescent probes for selective detection of Aβ aggregates in alzheimer's disease10.1021/acschemneuro.2c00361 ↗
83. Design of a coumarin-based fluorescent probe for efficient in vivo imaging of amyloid-β plaques10.1021/acschemneuro.2c00468 ↗
84. An AIE-active NIR fluorescent probe with good water solubility for the detection of aβ1–42 aggregates in alzheimer's disease10.3390/molecules28135110 ↗
85. Rational design synthesis and evaluation of a novel near-infrared fluorescent probe for selective imaging of amyloid-β aggregates in Alzheimer's disease10.1016/j.aca.2023.341900 ↗
86. Rational design of hydroxytricyanopyrrole-based probes with high affinity and rapid visualization for amyloid-β aggregates in vitro and in vivo
87. Near‐infrared bodipy‐based molecular rotors for β‐amyloid imaging in vivo10.1002/adhm.202300733 ↗
88. An activatable NIR‐II fluorescent reporter for in vivo imaging of amyloid‐β plaques10.1002/anie.202216351 ↗
89. Conformational features of the Aβ 42 peptide monomer and its interaction with the surrounding solvent10.1039/C6CP04925G ↗
90. Solution NMR studies of Aβ monomer dynamics[J10.2174/092986611794653969 ↗
91. The underexplored question of β-amyloid monomers10.1016/j.ejphar.2017.05.057 ↗
92. Compact fibril-like structure of amyloid β-peptide (1–42) monomers10.1039/D0CC06607A ↗
93. Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes10.1212/NXI.0000000000000237 ↗
94. Aβ oligomer elimination restores cognition in transgenic Alzheimer's mice with full-blown pathology10.1007/s12035-018-1209-3 ↗
95. Computational study on structure and aggregation pathway of Aβ42 amyloid protofibril10.1021/acs.jpcb.9b07195 ↗
96. Insights into the aggregation mechanism of Aβ (25–40)10.1016/j.bpc.2016.11.003 ↗